Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 17/20 | 0.60 |
| ▸ | CA2 | P00918 | 17/20 | 0.60 |
| ▸ | CA12 | O43570 | 4/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylsulfamide SCHEMBL1067535 | 0.78 | CA1 (0.95) | CA1CA2CA12CA9 | |
| SCHEMBL8909697 | 0.76 | PTPRB (0.39) | CA1CA2 | |
| SCHEMBL6232580 | 0.76 | PTPN11 (0.34) | CA1CA2CA12CA9 | |
| SCHEMBL1621848 | 0.76 | CA1 (0.35) | CA1CA2CA12CA9 | |
| SCHEMBL20032 | 0.76 | KEAP1 (0.60) | CA1CA2CA12CA9KIF11 | |
| Phenylsulfamide SCHEMBL253104 | 0.75 | CA1 (1.00) | CA1CA2CA12CA9 | |
| Phenylsulfamide SCHEMBL27994318 | 0.75 | CA1 (1.00) | CA1CA2CA12CA9 | |
| SCHEMBL28184919 | 0.74 | CA2 (0.57) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL6352180 | 0.73 | CA1 (0.64) | CA1CA2CA12CA9KIF11 | |
| SCHEMBL5684413 | 0.73 | CA1 (0.64) | CA1CA2CA12CA9KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268525-B1 | MACROCYCLIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS COMPRISING N-CYCLIC P2 MOIETIES | SCHERING CORP (US) | 2008-12-31 | — | — | EP | claimed |
| US-5208137-A | Pyrazolone merocyanine dye with carboxy or sulfonamide groups, aging stability, reduced fog | KONICA CORPORATION (JP) | 1993-05-04 | — | — | US | claimed |
| EP-0435561-A2 | Silver halide photographic light-sensitive material | KONICA CORPORATION (JP) | 1991-07-03 | — | — | EP | claimed |
| US-20180132516-A1 | POSITIVE ALLOSTERIC MODULATORS OF SWEET TASTE | SENSORYGEN INC (US) | 2018-05-17 | — | — | US | disclosed |
| US-9138427-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | N30 PHARMACEUTICALS, LLC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | BETSCHART CLAUDIA | 2009-02-26 | — | — | US | disclosed |
| CN-100372849-C | Pyrrolopyrimidines as cysteine protease inhibitors | NOVARTIS AG (CH) | 2008-03-05 | — | — | CN | disclosed |
| CN-1549817-A | Pyrrolo pyrimidines, process for their preparation, their use and pharmaceutical compositions containing them | ��˹��ŵ�� | 2004-11-24 | — | — | CN | disclosed |
| US-5208137-A | Pyrazolone merocyanine dye with carboxy or sulfonamide groups, aging stability, reduced fog | KONICA CORPORATION (JP) | 1993-05-04 | — | — | US | disclosed |
| US-5208137-A | Pyrazolone merocyanine dye with carboxy or sulfonamide groups, aging stability, reduced fog | KONICA CORPORATION (JP) | 1993-05-04 | — | — | US | disclosed |
| EP-0435561-A2 | Silver halide photographic light-sensitive material | KONICA CORPORATION (JP) | 1991-07-03 | — | — | EP | disclosed |
| EP-0435561-A2 | Silver halide photographic light-sensitive material | KONICA CORPORATION (JP) | 1991-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054467-A1 | Pyrrolo Pyrimidines as Agents for the Inhibition of Cystein Proteases | CTSK, CTSS, CTSZ | CA1 580/4885CA2 509/4885CA12 2663/4885 |
| US-20140194425-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | CA1 4697/4885CA2 4299/4885CA12 4860/4885 |
| US-20110144110-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | CA1 4697/4885CA2 4299/4885CA12 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.